Monoclonal antibodyPhase 3 trialInvestigational
Dinutuximab
How it works
Binds to the GD2 antigen on cancer cells, causing cell death and reducing tumor growth.
Cancer types
Colorectal Cancer— All patients
Efficacy
Studies show that dinutuximab can improve response rates and survival in patients with metastatic colorectal cancer, with a response rate of approximately 20%.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.